Some Articles on Mazdutide

[keangkong]

Here are some scholarly articles on mazdutide. I included hyperlinks to the full articles for most but not all of the citations. I used bold type for the article that I believe to be most revealing.

Anderson (2025). Emerging concepts in obesity managemen -: focus on glucagon receptor agonist combinations. Drugs Context, 14.

Deng, et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity - A systematic review and meta-analysis of randomized controlled trials. Endocrine, 86(1), 15-27. https://doi.org/10.1007/s12020-024-03857-6

Ji, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications, 14(1), 8289.

Ji, et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med, 392(22), 2215-2225.

Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine, 54.

Liu (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with-without type 2 diabetes - a systematic review and network meta-analysis. Frontiers in Endocrinology, 16, 1513641.

Moiz, et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes - a systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199-217. https://doi.org/10.7326/ANNALS-24-01590; https://www.acpjournals.org/doi/abs/10.7326/ANNALS-24-01590.

Nalisa, et al. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients - a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 15, 1309118.

Newswire, P. R. Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.

Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 161, 156038.

Zhang, et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes 0 a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.

 

[keangkong]

Here is an updated version. I'm struggling to learn as much about mazdutide as I can before my first order arrives. It's supposed to arrive on Monday.

Anderson (2025). Emerging concepts in obesity management - focus on glucagon receptor agonist combinations. Drugs Context, 14.

Bhattachar, et al. (pre-publication, 2025-08-20). Mazdutide reduces body weight in adults with overweight or obesity - A high-dose Phase 1 trial. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70040.

Cheng, et al. (2025). Efficacy and Safety of Dose-Escalated Mazdutide, a GLP-1/GCGR Dual Agonist, in an Adolescent with Obesity, Type 2 Diabetes, and Hyperuricemia - A Case Report. Frontiers in Endocrinology, 16, 1654506.

Deng, et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity - A systematic review and meta-analysis of randomized controlled trials. Endocrine, 86(1), 15-27.

Dong, et al. (2025). Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction - mechanistic insights from multiomics analysis. EBioMedicine, 117. Obesity Pillars, 13, 100162.

Guo, et al. (2025). Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction - A model-based meta-analysis of placebo-controlled trials.

Guo, et al. (2024). Mazdutide vs dulaglutide in patients with type 2 diabetes (DREAMS-2) - a randomised, open-label, 28-week phase 3 trial. Diabetologia. 2024;67(1 Suppl):S516–7.

Ji, et al. (2024). 1856-LB - Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1). Diabetes 2024;73(Supplement_1):1856-LB.

Ji, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications, 14(1), 8289.

Ji, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity - A randomised, placebo-controlled, multiple ascending dose phase 1b study. eClinicalMedicine, 39, 101088.

Ji, et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med, 392(22), 2215-2225.

Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine, 54.

Jiang, et al. (2025). A phase 2 study of mazdutide 9 mg in Chinese adults with BMI≥30 kg/m2 [abstract]. Diabetologia. 2024;67(1 Suppl):S351–2.

Jinhua & Li. Jinhua, Z., & Li, R. Structural Insights into Multiplexed Pharmacological Actions of Mazdutide At the Glp-1 or Glucagon Receptors. (2025, pre-publication).

Liu (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with-without type 2 diabetes - a systematic review and network meta-analysis. Frontiers in Endocrinology, 16, 1513641.

Madsbad & Holst (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity - a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs, 34(3), 197-215.

Melson, et al. (2025). What is the pipeline for future medications for obesity[Q] Int'l J. Obesity 49, 433–451.

Moiz, et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes - a systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199-217.

Nalisa, et al. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients - a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 15, 1309118.

Novikoff & Muller (2023). The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides, 165, 171003.

Newswire, P. R. Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.

Shirley (pre-publication, 2025). Mazdutide - First Approval. Drugs. https://doi.org/10.1007/s40265-025-02249-y

Stachteas, et al. (2025). Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum - A Review of Current Clinical Evidence. Rev. Cardiovasc. Med., 26(7), 39691.

Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 161, 156038.

Winther & Holst (2024). Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. Diabetes, Obesity and Metabolism, 26(9), 3501-3512.

Wu, et al. (2025). 777-P - The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation. Diabetes, 74(Supplement_1), 777-P.

Zhang, et al. (2023). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes - a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.

Zhu, et al. (2025). 306-OR - Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1). Diabetes 2025;74(Supplement_1):306-OR.

 

[keangkong]

Here is an update:

Mazdutide prescribing instructions - a summary of the Chinese.

Mazdutide prescribing instructions translated into English. This is not easy to read.

Mazdutide prescribing directions - in the original Chinese.

Ayesh, et al. (2024). Letter to the Editor - Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management - Meta-Analysis of Randomized Controlled Trials. Am. J. Therapeutics 31(5), e619-3622.

Bailey, et al. (2025). Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides 187, 171380.

Forst, et al. (2024). The role of incretin receptor agonists in the treatment of obesity. Diabetes Obesity Metabolism 26(10), 4178-4196.

Gogineni, et al. (2024). Expert Opin Pharmacother. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes - where are we now[Q] Expert Opn. Pharmacother. 25(7), 801-818.

Innovent Biologic (Sep. 19, 2025). Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes.

Ji, et al. (2024). 1856-LB - Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1). Diabetes 73(Supplement_1).

Ji, et al. (2024). 857-LB - Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1. Diabetes 73 (Supplement_1).

Ji, et al. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity - A randomised, placebo-controlled, multiple ascending dose phase 1b study. eClinicalMedicine, 39, 101088.

Jiang, et al. (2022). A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature Comm. 13(1), 3613.

Kokkorakis, et al. (2025). Emerging pharmacotherapies for obesity - a systematic review. Pharmacol. Rev. 77(1), 100002.

Lee, et al. (2025). Glucagon in metabolic disease - a mini-review of emerging multi-organ roles beyond glycemic control. Frontiers Endocrinol. 16, 1645041.

McGlone & Tan (2024). Glucagon-based therapy for people with diabetes and obesity - what is the sweet spot[Q] Peptides 176, 171219.

Neff (pre-publication, 2025). Shared mechanistic pathways of glucagon signalling - Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70148.

Newswire, P. R. Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.

Sidrak, et al. (2024). Approved and Emerging Hormone-Based Anti-Obesity Medications - A Review Article. Indian J. Endocrinol. & Metabolism 28(5), 445-460.

Son, et al. (pre-publication, 2025). Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity. Endocrine Rev., https://doi.org/10.1210/endrev/bnaf036.

Xia, et al. (2025). Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiol. 316(2), e243780.

Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism 161, 156038.

Zhang, et al. (2025). Focus on Glucagon-like Peptide-1 Target - Drugs Approved or Designed to Treat Obesity. Int'l J. Molecular Pharmacol. 26(4), 1651.

Zhang, et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes - a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.

Zhang & Li (2025). Structural Insights into Multiplexed Pharmacological Actions of Mazdutide At the Glp-1 or Glucagon Receptors. (2025, pre-publication).

 

[conzopiriani]

Thank you! Putting on specks and flipping up the foot rest.

 

[keangkong]

Thank you! Putting on specks and flipping up the foot rest.

You're welcome. I had to do so. My mazdutide is supposed to arrive on Monday. I have to psych myself out or else I'll get pissed off about some side effect or decide to give up because I'm hungry 1 1/2 hours after I take it for the first time. I think I like that half life; I may actually take it only once per week since the half life is about 8 days.